Bimekizumab given by vein or by injection in psoriatic arthritis and axial spondyloarthritis
Compares bimekizumab given by vein or injection in adults with active joint disease.
Plain-language title generated from the registry record
Registry title: A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Key facts
- Where
- Košice and Piešťany, SlovakiaSee the 3 sites
- Phase
- Phase 1
Where in Slovakia
- Pa0019 601Košice, SlovakiaTaking people
- Pa0019 602Košice, SlovakiaTaking people
- Pa0019 603Piešťany, SlovakiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UCB Biopharma SRL
- Trial code
- NCT07290036
- Record updated
- 6 November 2026
- Original description
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.Read full original descriptionShow less
An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
Inclusion: Be 18+ years old and legally able to consent; Have active psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), suitable for bimekizumab treatment; Weigh between 45-100 kg (females) or 50-100 kg (males); Be biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve or have stopped bDMARDs ≥3 months or 5 half-lives ago.
Exclusion: Recent live vaccines (within 8 weeks) or Bacillus Calmette-Guerin (BCG) (within 1 year); Serious organ system disorders (e.g., heart, liver, kidney, gastrointestinal, neuro); Severe psychiatric issues or substance abuse in the past year; Recent or chronic infections, including tuberculosis (TB) or nontuberculous mycobacterium (NTMB); Other inflammatory diseases (e.g., rheumatoid arthritis (RA), lupus, inflammatory bowel disease (IBD)); Recent use of glucagon-like peptide-1 (GLP-1) agonists (within 28 weeks).